167 related articles for article (PubMed ID: 26348946)
1. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
Schmidt C
Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
[No Abstract] [Full Text] [Related]
2. New plaque psoriasis approval carries suicide warning.
Mullard A
Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248935
[No Abstract] [Full Text] [Related]
3. No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.
Strober BE; Langley RGB; Menter A; Magid M; Porter B; Fox T; Safi J; Papavassilis C
Br J Dermatol; 2018 Feb; 178(2):e105-e107. PubMed ID: 28991372
[No Abstract] [Full Text] [Related]
4. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.
Nijsten T; Spuls PI
Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593
[No Abstract] [Full Text] [Related]
5. Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan C
Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
[No Abstract] [Full Text] [Related]
6. Rebound pustular psoriasis after brodalumab discontinuation.
Khemis A; Cavalié M; Montaudié H; Lacour JP; Passeron T
Br J Dermatol; 2016 Nov; 175(5):1065-1066. PubMed ID: 27037661
[No Abstract] [Full Text] [Related]
7. Guselkumab (Tremfya) for psoriasis.
Med Lett Drugs Ther; 2017 Nov; 59(1533):179-180. PubMed ID: 29125591
[No Abstract] [Full Text] [Related]
8. Ustekinumab (Stelara) for psoriasis.
Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
[No Abstract] [Full Text] [Related]
9. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
[No Abstract] [Full Text] [Related]
10. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States.
Danesh MJ; Kimball AB
J Am Acad Dermatol; 2016 Jan; 74(1):190-2. PubMed ID: 26702804
[No Abstract] [Full Text] [Related]
11. Multiple eruptive dermatofibromas in a patient receiving efalizumab.
Santos-Juanes J; Coto-Segura P; Mallo S; Galache C; Soto J
Dermatology; 2008; 216(4):363. PubMed ID: 18292655
[No Abstract] [Full Text] [Related]
12. [Infliximab].
Herrera E; Habicheyn S
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
[TBL] [Abstract][Full Text] [Related]
13. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
14. [Up-date on the use of infliximab in dermatology. Introduction].
Sánchez-Carazo J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():1. PubMed ID: 19080984
[No Abstract] [Full Text] [Related]
15. [Personal experience with the use of infliximab].
Carretero G
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():36-42. PubMed ID: 19080990
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis: the future.
Menter MA; Griffiths CE
Dermatol Clin; 2015 Jan; 33(1):161-6. PubMed ID: 25412790
[TBL] [Abstract][Full Text] [Related]
17. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Dressler C; Rosumeck S; Werner RN; van der Kraaij G; van Lumig P; Wakkee M; Spuls P; Nast A
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1964-1977. PubMed ID: 28944515
[No Abstract] [Full Text] [Related]
18. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
19. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.
Masson Regnault M; Konstantinou MP; Khemis A; Poulin Y; Bourcier M; Amelot F; Bulaï Livideanu C; Paul C
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1491-1496. PubMed ID: 28585707
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis: from bed to bench and back.
Garber K
Nat Biotechnol; 2011 Jul; 29(7):563-6. PubMed ID: 21747375
[No Abstract] [Full Text] [Related]
[Next] [New Search]
